# Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

> **NCT02574455** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 529 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Eribulin
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT02574455
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-07
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-12-08
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574455, "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02574455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*